åêðáéäåõóçó γ.ν.α.

ΝΟΣΟΚΟΜΕΙΑΚΑ ΧΡΟΝΙΚΑ, ΤΟΜΟΣ 71, ΣΥΜΠΛΗΡΩΜΑ, 2009
333
ΒΙΒΛΙΟΓΡΑΦΙΑ
1. Diabetes Statistics. October 1995 (updated 1997). NI-
DDK publication NIH 96-3926. Harris MI. In: Diabetes
in America. 2nd ed. 1995:1-13.
2. Polonski KS. The B-cell in diabetes. From molecular
genetics to clinical research. Diabetes 1995; 44, 705-
717.
3. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis
of NIDDM. A balanced overview. Diabetes Care.
1992;15(3):318-68.
4. Heinemann L, Linkeshova R, Rave K et al. Time-action
profile of the long-acting insulin analog insulin glargine
in comparison with those of NPH insulin and placebo.
Diabetes Care 2000; 23: 644-649
5. Buse J. Insulin Glargine. First responsibilities: understanding
the data and ensuring safety. Diabetes Care
2000; 23: 576-578.
6. Kurtzhals P. Engineering predictability and protraction
in a basal insulin analogue: the pharmacology of insulin
detemir. Int J Obes Relat Metab Disord. 2004;28(Suppl
2):S23-8.
7. Rosenstock J et al Insulin detemir added to oral antidiabetic
drugs in type 2 diabetes provides glycemic
control camparable to insulin glargine with less weigh
gain. Diabetes 2006;55 (Suppl) A132
8. Hirsch IB. Insulin analogues. N Engl J Med 2005; 352:
174-183
9. Home P, Lidholm A, Ris A. Insulin aspart vs. human
insulin in the management of longterm blood glucose
control in type 1 diabetes mellitus: a randomised controlled
trial. Diabet Med 2000; 17: 762-770.
10. Heller S, Colagiuri S, Vaaler S et al. Reduced hypoglycaemia
with insulin aspart in type 1 diabetes: a doubleblind,
randomised, cross-over trial. Diabetes 2001; 50, (suppl.
2): A137.
11. Siebenhofer A, Plank J, Berghold A al. Short acting insulin
analogues versus regular human insulin in patients with
diabetes mellitus. Cochrane Database Syst Rev 2004;
4: CD003287.
12. American College of Endocrinology Consensus Statement
on Guidelines for Glycemic Control.
13. American College of Endocrinology Consensus Statement
on Guidelines for Glycemic Control, 2001. Endocr
Pract. 2002;8(suppl 1):5-11.
14. The Diabetes Control and Complications Trial Research
Group. The effect of intensive treatment of diabetes on
the development and progression of long-term complications
in insulin-dependent diabetes mellitus. N Engl
J Med. 1993;329:977-86.
15. UK Prospective Diabetes Study (UKPDS 33) Group.
Intensive blood-glucose control with sulphonylureas
or insulin compared with conventional treatment and
risk of complications in patients with type 2 diabetes.
Lancet. 1998;352:837-53.
16. Raskin P, Allen E, Hollander P, et al. Initiating insulin
therapy in type 2 diabetes: a comparison of biphasic
and basal insulin analogs. Diabetes Care. 2005;28:260-
265.
17. Riddle MC, Rosenstock J, Gerich J. The Treat-to-Target
trial: randomized addition of glargine or human NPH
insulin to oral therapy of type 2 diabetic patients. Diabetes
Care. 2003;26:3080-3086.
18. Hermansen K, Davies M, Derezinski T et al. A 26-week,
randomized, parallel, treat-to-target trial comparing
insulin detemir with NPH insulin as add-on therapy to
oral glucose-lowering drugs in insulin-naοve people with
type 2 diabetes. Diabetes Care. 2006;29:1269-1274.
19. Standl E, Maxeiner S, Raptis S. Once-daily insulin glargine
administration in the morning compared to bedtime in
combination with morning glimepiride in patients with
type 2 diabetes: an assessment of treatment flexibility.
Horm Metab Res. 2006;38:172-177.
20. Eliaschewitz FG, Calvo C, Valbuena H, et al. Therapy in
type 2 diabetes: insulin glargine vs. NPH insulin both in
combination with glimepiride. Arch Med Res. 2006;37:
495-501
21. Holman RR, Thorne KI, Farmer AJ et al. Addition of biphasic,
prandial, or basal insulin to oral therapy in type
2 diabetes. N Engl J Med. 2007;357(17):1716-30
xxxxxxxxxxx
xxxxxx